We partner with the media to inform the public of the global human crisis.
Our Commitment
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
Latest News
-
June 18, 2019
Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE® (buprenorphine and naloxone) Sublingual Film... -
June 17, 2019
New Data from the RECOVER™ Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting... -
June 4, 2019
Jefferies 2019 Global Healthcare Conference Presentation... -
May 16, 2019
Indivior to present at Jeffries 2019 Healthcare Conference... -
May 9, 2019
Indivior Enters into Exclusive License Agreement with HLS Therapeutics for PERSERIS™ (risperidone) in Canada...
Upcoming Events
Global Media Contacts
Email: IndiviorMediaContacts@indivior.com
Phone: +1 804-594-0836
UK Media Contacts
Tulchan Communications LLP
85 Fleet Street
London
EC4Y 1AE
Indivior@Tulchangroup.com
Phone: +44 (020) 7353 4200
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
Media Kit
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline